Abstract:figure legend Circulating noradrenaline (NA) stimulates the release of neuropeptide Y (NPY) from presynaptic sympathetic nerve terminals via activation of β‐adrenergic receptors (β‐R). This NA‐induced NPY release can be inhibited by the β‐blocker propranolol, suggesting that this mechanism, which enhances sympathoexcitation, is mediated via β‐adrenergic receptors. Cardiac disease is marked by sympathoexcitation and elevated levels of noradrenaline (NA) and cotransmitter neuropeptide Y (NPY). Increased NPY levels are associated with a greater risk of ventricular arrhythmias and mortality. Nonetheless, the factors that cause NPY release remain poorly understood. We hypothesized that circulating catecholamines might lead to NPY release from myocardial sympathetic nerve terminals via a β‐receptor‐mediated mechanism that enhances sympathoexcitation. Ventricular interstitial NA and NPY levels were measured in six Yorkshire pigs after i.v. administration of NA (1 mg) and before and after propranolol infusion (1 mg/kg). Real‐time interstitial NPY levels were measured using ventricular capacitive immunoprobes (CIs) affixed with NPY antibodies and quantified as the change in CI input current (INPY) upon binding of NPY. Interstitial NA was measured with adjacent fast‐scan cyclic voltammetry probes (INA). A left ventricular pressure catheter and continuous ECGs were used for haemodynamic recordings, and an epicardial 56‐electrode sock was used for measurements of activation recovery interval, a surrogate of action potential duration. Upon administration of NA, heart rate and left ventricular pressure increased, and activation recovery interval shortened. Notably, NA significantly increased interstitial myocardial NPY levels. After propranolol, changes in heart rate and activation recovery interval were largely mitigated. The INA increased to a similar extent post‐propranolol vs. pre‐propranolol, but changes in INPY were significantly reduced post‐propranolol. Coronary sinus plasma analyses confirmed fast‐scan cyclic voltammetry and CI findings. Hence, this study demonstrates that circulating NA induces NPY release from ventricular sympathetic nerve terminals, the mechanism for which is mediated via β‐adrenergic receptors and can be blocked by the non‐selective β‐blocker, propranolol. Key points Cardiovascular disease is characterized by sympathovagal imbalance, with increased plasma noradrenaline (NA) and neuropeptide Y (NPY) concentrations. Increased NPY levels are associated with increased ventricular arrhythmias and mortality in heart failure. Limited data are available on the specific factors that cause NPY release. In this study, fast‐scan cyclic voltammetry and capacitive immunoprobes were used to allow for real‐time in vivo measurements of interstitial myocardial neurotransmitters and neuropeptides, respectively. Using an in vivo porcine model with cardiac fast‐scan cyclic voltammetry and capacitive immunoprobes, it was shown that systemic NA can increase ventricular interstitial NPY levels, suggesting that NA induces NPY release from postganglionic sympathetic nerves. The release of NPY was blocked by administration of the non‐selective β‐blocker propranolol, suggesting that release of NPY is dependent on activation of β‐adrenergic receptors by NA.

Human sympathetic neuronal discharge and recruitment patterns regulate neuropeptide Y bioavailability

Central α2-adrenergic mechanisms regulate human sympathetic neuronal discharge strategies

Excessive Penile Norepinephrine Level Underlies Impaired Erectile Function in Adenosine A1 Receptor Deficient Mice

Tonic Nmda Receptor-Mediated Inward Current In Pre-Sympathetic Pvn Neurons Is Enhanced By Heart Failure.

Circulating noradrenaline leads to release of neuropeptide Y from cardiac sympathetic nerve terminals via activation of β‐adrenergic receptors

Neuropeptide Y: Direct vasoconstrictor and facilitatory effects on P2X1 receptor-dependent vasoconstriction in human small abdominal arteries

The cardiac sympathetic co-transmitter neuropeptide-Y is pro-arrhythmic in human cardiomyocytes by lengthening activation-recovery interval

Relationship between regional sympathetic vascular transduction and sympathetic transduction of blood pressure in young adults at rest

Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions

Bayliss Starling Prize Lecture 2023: Neuropeptide‐Y being 'unsympathetic' to the broken hearted

Kinetics of neuropeptide Y, catecholamines, and physiological responses during moderate and heavy intensity exercises

Synergism between neuropeptide Y and norepinephrine highlights sympathetic cotransmission: studies in rat arterial mesenteric bed with neuropeptide Y, analogs, and BIBP 3226

Enhanced neuropeptide Y immunoreactivity and vasoconstriction in mesenteric small arteries from spontaneously hypertensive rats

Interaction of simultaneous hypoxia and baroreflex loading on control of sympathetic action potential subpopulations

An Animal And Clinical Study On The Change Of Neuropeptide Y Release Evoked By Electrical Stimulation And Myocardial Ischemia

Both coiling and clipping induce the time-dependent release of endogenous neuropeptide Y into serum

Systemic and cavernous plasma levels of neuropeptide Y during sexual arousal in healthy males

Neuropeptide Y induced increase of cytosolic and nuclear Ca2+ in heart and vascular smooth muscle cells

Neuropeptide Y. A novel sympathetic stress hormone and more

Sympathetic determinants of resting blood pressure in males and females

Sympathetic transduction of cardiac sympathetic nerve activity in healthy, conscious sheep